CIN (n = 14)

No CIN (n = 172)

P

Male/Female

12/2

124/48

0.3587

Age (Years)

70.8 ± 6.2

72.6 ± 8.2

0.4837

HT (%)

5 (36%)

70 (41%)

0.7147

DM (%)

5 (36%)

60 (35%)

0.8190

SCr (mg/dl)

0.80 ± 0.22

0.84 ± 0.22

0.7745

eGFR (mL/min/1.73 mm²)

76.2 ± 23.7

68.4 ± 19.0

0.5561

eGFR < 60 mL/min (%)

5 (36%)

68 (40%)

0.7783

Previous TACE sessions

3.4 ± 3.0

2.5 ± 2.6

0.3461

Multiple HCC (%)

10 (71%)

117 (68%)

0.9718

Diameter max HCC (mm)

37.0 ± 35.8

28.4 ± 18.8

0.2895

Contrast volume (mL)

154 ± 43

147 ± 45

0.4671

Chemotherapy

0.1668

Miriplatin

3

75

Cisplatin

11

78

Epirubisin

2

19

Child-Pugh class B or C

10 (71%)

70 (41%)

0.0459^*

Ascites

2 (14%)

29 (17%)

0.5883

HBsAg-positive

3 (21%)

15 (8.7%)

0.2817

HCVAb-positive

9 (64%)

121 (70%)

0.8629

Albumin (g/dl)

3.0 ± 0.5

3.4 ± 0.6

0.0175^*

Total bilirubin (mg/dl)

1.0 ± 0.5

0.9 ± 0.5

0.1940

AST (mg/dl)

70.8 ± 54.0

59.7 ± 40.4

0.6739

ALT (mg/dl)

50.7 ± 45.2

47.3 ± 42.0

0.7391

Prothrombin time (INR)

1.16 ± 0.31

1.22 ± 0.81

0.2794

Platelet count

11.7 ± 6.2

11.8 ± 5.4

0.7725

Hemoglobin

10.6 ± 2.0

11.8 ± 2.0

0.0351^*

AFP (ng/mL)

1105 ± 3132

842 ± 2074

0.6029

PIVKA-II (IU/mL)

249 ± 455

1854 ± 6688

0.1969